15 Skyline Drive
About Acorda TherapeuticsAcorda Therapeutics is a privately held biotechnology company developing therapies for spinal cord injury (SCI) and related neurological conditions, including multiple sclerosis (MS). The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 for MS.
Fampridine-SR acts to combat the effects of demyelination in the spinal cord. Myelin is the insulating sheath around nerve processes; when it is damaged due to trauma or disease, electrical impulses from the brain cannot be conducted past the demyelinated area. Fampridine-SR chemically blocks the exposed voltage-gated potassium channels, allowing the impulse from the brain to be conducted more normally past the area of damage. Fampridine is being studied in Phase 3 clinical trials to evaluate its efficacy in reducing spasticity in people with chronic spinal cord injury. Secondary endpoints in the study include evaluating its effect on bladder, bowel, and sexual function. The Company is also conducting a 152 patient, late Phase 2 clinical study in MS to evaluate Fampridine-SR's efficacy in walking speed and muscle strength.
Acorda's technology platform also includes two remyelinating agents in preclinical development for MS. The first is M1, a class of human monoclonal antibodies that have been shown to remyelinate the central nervous system in animal models, and the second is GGF2, a product of the neuregulin 1 gene. Preclinical studies have shown that GGF2 can stimulate the cell growth necessary to protect and regenerate damaged myelin. Additionally, Acorda is developing protein- and stem cell-based technologies for regeneration and repair of the spinal cord and brain.
In 2002, Acorda was the recipient of the National Spinal Cord Injury Association's L. W. Freeman Award for scientific research.
Ron Cohen, M.D., President and CEO Andrew R. Blight, Ph.D., Executive Vice President, Research & Development Mary Fisher, Vice President, Marketing and Strategic Planning Elliott A. Gruskin, Ph.D., Vice President, Research & Development Mitchell Katz, Ph.D., Vice President, Clinical Programs David Lawrence, Vice President, Finance Mark R. E. Pinney, C.F.A., Chief Financial Officer and Director Harold Safferstein, Ph.D., J.D., Vice President, Business Development
Last Updated: 05-09-03
504 articles with Acorda Therapeutics
“Do Tell” Your Doctor Tool was adapted from a clinically validated questionnaire developed by Duke University, with input from the Parkinson’s community
Acorda Therapeutics, Inc. will host a conference call and webcast to report its third quarter 2019 update and financial results on Monday, November 4 at 4:30 p.m. ET.
Acorda Therapeutics’ attempt to preserve its patent protection for multiple sclerosis drug Ampyra hit the proverbial wall Monday when the U.S. Supreme Court refused to hear the company’s appeal of a lower court ruling.
Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Friday, October 4 at 11:15AM ET.
Acorda Therapeutics, Inc. announced that it will present data at the International Congress of Parkinson’s Disease and Movement Disorders, taking place September 22-26, 2019 in Nice, France.
Acorda Therapeutics, Inc. (NASDAQ: ACOR) provided a financial and pipeline update for the quarter ended June 30, 2019.
Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending INBRIJA’s approval by the European Commission (EC).
Acorda Therapeutics, Inc. will host a conference call and webcast to report its second quarter 2019 update and financial results on Thursday, August 1 at 4:30 p.m. ET.
Acorda Therapeutics Debuts Art Exhibition Inspired by People with Parkinson’s at the 5th World Parkinson Congress
Acorda Therapeutics, Inc. announced that it will debut an art gallery inspired by people with Parkinson’s at the 5th World Parkinson Congress in Kyoto, Japan.
Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Wednesday, June 5 at 8:00AM EST.
INBRIJA™ (levodopa inhalation powder) commercially available on February 28; first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa
Acorda Therapeutics, Inc. will host a conference call and webcast to report its first quarter 2019 update and financial results on Thursday, May 2 at 8:30 a.m. ET.
Acorda to Present New Long-Term Data for INBRIJA™ (levodopa inhalation powder) at Academy of Managed Care Pharmacy Annual Meeting
Acorda Therapeutics, Inc. will present three posters with Phase 3 data on INBRIJA at the upcoming Academy of Managed Care Pharmacy Managed Care & Specialty Pharmacy Annual Meeting taking place March 25-28, 2019, in San Diego.
First and Only FDA-Approved Inhaled Levodopa for On-demand Use for OFF Periods in People with Parkinson’s Taking Carbidopa/Levodopa
Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will present at the Cowen and Company Global Health Care Conference on Monday, March 11 at 1:30PM EST.
Acorda Therapeutics, Inc. announced that Andrew Hindman, Acorda’s Chief Business Officer, will present at the Leerink Global Healthcare Conference on Wednesday, February 27 at 11:00 a.m. EST.
Acorda Therapeutics, Inc. provided financial and pipeline updates for the fourth quarter and full year ended December 31, 2018.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Peter S. Carbone has joined the Company as Senior Vice President, Quality.
Acorda Therapeutics, Inc. will host a conference call and webcast in conjunction with its fourth quarter/year end 2018 update and financial results on Thursday, February 14 at 4:30 p.m. ET.
Acorda Announces The Lancet Neurology Publication of Phase 3 Data for INBRIJA™ (levodopa inhalation powder)
SPAN℠-PD, the efficacy and safety study of INBRIJA (CVT-301), showed significant improvement in motor function during OFF periods in people with Parkinson’s on a carbidopa/levodopa regimen